Unique behavior of brain metastases during the treatment of nivolumab for metastatic renal cell carcinoma.
作者信息
Kondo Tsunenori, Ishihara Hiroki
机构信息
Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S267. doi: 10.21037/atm.2019.12.46.
Abstract
摘要
相似文献
1
Unique behavior of brain metastases during the treatment of nivolumab for metastatic renal cell carcinoma.纳武单抗治疗转移性肾细胞癌期间脑转移瘤的独特表现
Ann Transl Med. 2019 Dec;7(Suppl 8):S267. doi: 10.21037/atm.2019.12.46.
2
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.纳武利尤单抗治疗肾细胞癌脑转移的安全性和疗效：GETUG-AFU 26 NIVOREN 多中心 II 期研究结果。
J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13.
3
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.纳武利尤单抗治疗转移性肾细胞癌患者的疾病进展模式、预测因素和后续结局。
J Immunother Cancer. 2018 Oct 17;6(1):107. doi: 10.1186/s40425-018-0425-8.
4
Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.在接受纳武单抗治疗转移性肾细胞癌后获得持久完全缓解的患者中观察到白癜风不良事件。
Front Oncol. 2019 Oct 9;9:1033. doi: 10.3389/fonc.2019.01033. eCollection 2019.
5
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.纳武利尤单抗治疗转移性肾细胞癌的安全性和疗效：扩展准入计划的真实世界结果。
BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23.
6
[Clinical Effect of Nivolumab on Advanced Renal Cell Carcinoma with Peritoneal Metastasis].纳武利尤单抗治疗晚期肾细胞癌伴腹膜转移的临床疗效
Hinyokika Kiyo. 2019 Oct;65(10):413-419. doi: 10.14989/ActaUrolJap_65_10_413.
7
[Initial Clinical Experience of Nivolumab for Metastatic Renal Cell Carcinoma].纳武单抗治疗转移性肾细胞癌的初步临床经验
Hinyokika Kiyo. 2018 Oct;64(10):383-389. doi: 10.14989/ActaUrolJap_64_10_383.
8
Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.使用血液参数对日本转移性肾细胞癌患者进行纳武利尤单抗风险分层的预后价值。
Jpn J Clin Oncol. 2020 Feb 17;50(2):214-220. doi: 10.1093/jjco/hyz168.
9
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.纳武利尤单抗和卡博替尼治疗转移性肾细胞癌的真实世界结局：来自国际转移性肾细胞癌数据库联盟的结果。
Curr Oncol. 2019 Apr;26(2):e175-e179. doi: 10.3747/co.26.4595. Epub 2019 Apr 1.
10
[A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].[一例转移性肾细胞癌患者发生的迟发性纳武单抗诱导的间质性肾炎病例]
Hinyokika Kiyo. 2019 May;65(5):157-161. doi: 10.14989/ActaUrolJap_65_5_157.
本文引用的文献
1
Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study.脑转移瘤来自肾细胞癌：一项机构研究。
Clin Genitourin Cancer. 2019 Dec;17(6):e1163-e1170. doi: 10.1016/j.clgc.2019.08.006. Epub 2019 Aug 20.
2
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.纳武利尤单抗治疗肾细胞癌脑转移的安全性和疗效：GETUG-AFU 26 NIVOREN 多中心 II 期研究结果。
J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13.
3
Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.纳武利尤单抗和伊匹单抗颅内抗肿瘤反应：药效学和药代动力学视角，范围系统性综述。
BMC Cancer. 2019 May 30;19(1):519. doi: 10.1186/s12885-019-5741-y.
4
Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions.纳武单抗治疗转移性肾细胞癌期间新发脑转移瘤：日本两家机构的病例系列报道
Int J Urol. 2019 Aug;26(8):849-850. doi: 10.1111/iju.14020. Epub 2019 May 21.
5
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.欧洲泌尿外科学会肾癌指南：2019 年更新版。
Eur Urol. 2019 May;75(5):799-810. doi: 10.1016/j.eururo.2019.02.011. Epub 2019 Feb 23.
6
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.纳武利尤单抗治疗转移性肾细胞癌患者的疾病进展模式、预测因素和后续结局。
J Immunother Cancer. 2018 Oct 17;6(1):107. doi: 10.1186/s40425-018-0425-8.
7
Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study.纳武利尤单抗治疗转移性肾细胞癌患者的即刻进展性疾病：一项多机构回顾性研究。
Target Oncol. 2018 Oct;13(5):611-619. doi: 10.1007/s11523-018-0591-0.
8
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.纳武利尤单抗联合伊匹单抗治疗脑转移黑色素瘤。
N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.
9
Utilization of Stereotactic Radiosurgery for Renal Cell Carcinoma Brain Metastases.立体定向放射外科治疗肾细胞癌脑转移。
Clin Genitourin Cancer. 2018 Aug;16(4):e935-e943. doi: 10.1016/j.clgc.2018.03.015. Epub 2018 Apr 3.
10
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
Zotero 插件